Barclays’s Immunocore IMCR Stock Holding History
Bought
Maintained
Sold
Other funds holding IMCR
RI
BG
TCM
VPC
AC
Barclays's IMCR Position: Q2 2026 in Review
Barclays reduced its Immunocore (IMCR) stake by 4.5% in Q2 2026, selling an estimated $41.2K and leaving 29,517 shares worth $937K. The position accounts for ﹤0.01% of the portfolio, ranked #2828.
Barclays first reported a position in IMCR in Q1 2022 and has held it in 18 quarters since. The position peaked at $11.8M in Q2 2023. 136 funds tracked by Wall St. Rank hold IMCR as of Q2 2026.
- Barclays held 29,517 shares of Immunocore worth $937K as of Q2 2026.
- Barclays sold 1,392 Immunocore shares in Q2 2026, an estimated $41.2K.
- Immunocore made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #2828 holding.
- Barclays first reported a position in Immunocore in Q1 2022 and has held it in 18 quarters since.
- Barclays's Immunocore position peaked at $11.8M in Q2 2023.
- 136 funds tracked by Wall St. Rank held Immunocore as of Q2 2026.
Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.